Drugs / Bifidobacterium breve B632
Bifidobacterium breve B632
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT03261466 Comparator | Nov 2013 → Oct 2017 | obesity disorder | Azienda Ospedaliero Universitaria Maggiore della Carita | Completed | No outcome recorded |
| Phase 4 | NCT03219931 Comparator | Oct 2013 → Jul 2017 | — | Azienda Ospedaliero Universitaria Maggiore della Carita | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bifidobacterium breve B632 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03219931 ↗ |
| Known as | B. breve B632 | “101 youths (6-18 years, Tanner stage ≥2) with obesity and insulin-resistance on diet were randomized to 2 × 109 CFU/AFU/day of Bifidobacterium breve BR03 (DSM 16604) and B....” PMID 34229263 ↗ Jun 2021 |
| Known as | B632 | “101 youths (6-18 years, Tanner stage ≥2) with obesity and insulin-resistance on diet were randomized to 2 × 109 CFU/AFU/day of Bifidobacterium breve BR03 (DSM 16604) and B....” PMID 34229263 ↗ Jun 2021 |
| Known as | DSM 24706 | “101 youths (6-18 years, Tanner stage ≥2) with obesity and insulin-resistance on diet were randomized to 2 × 109 CFU/AFU/day of Bifidobacterium breve BR03 (DSM 16604) and B....” PMID 34229263 ↗ Jun 2021 |
| Action | Inhibit | “Both bifidobacteria strains showed, during an in vitro study, the ability to oppose 4 strains of E. coli;” NCT03219931 ↗ |